From 3d55adaa4ed40e7364ae3c35f063a106d6bca549 Mon Sep 17 00:00:00 2001 From: beantownbabe <156287695+beantownbabe@users.noreply.github.com> Date: Tue, 18 Aug 2026 10:53:57 +0200 Subject: [PATCH] Track market_intelligence.html to prevent data loss This file was untracked and held 5 prospects (Bosch, Volkswagen PowerCo, Infineon Technologies, Verkor, TSMC Dresden) not present in the live index.html version, with no backup anywhere. Committing it preserves that data while the discrepancy between the two files gets resolved. Co-Authored-By: Claude Sonnet 5 --- market_intelligence.html | 970 +++++++++++++++++++++++++++++++++++++++ 1 file changed, 970 insertions(+) create mode 100644 market_intelligence.html diff --git a/market_intelligence.html b/market_intelligence.html new file mode 100644 index 0000000..7f8204d --- /dev/null +++ b/market_intelligence.html @@ -0,0 +1,970 @@ + + + + + +TXproducts Market Intelligence + + + + +
+
+ + TXproducts logo +
+ TXproducts + Market Intelligence +
+ + +
26 Jun 2026
+
+
+ +
+ + +
+
+
Synchrotron Beamtime-as-a-Service: Market Overview
+
Global market sizing, growth trajectory, and pricing benchmarks
+
+
Data sourced from market research reports and facility documents. Some figures are from commercial market reports (not independently audited). Use as directional benchmarks.
+
+
Global Synchrotron Market (2025)
$1.5B
Total market value USD
+9.2% CAGR
+
Projected Market (2034)
$3.2B
9-year forecast
2.1x growth
+
Proprietary Beamtime Rate
$790
Per hour, NSLS-II FY2026
+2 hr minimum
+
Industrial Share of Users
~5%
ESRF 2011-2021 (non-academic)
Large white space
+
+
+
+
Market Segments by Instrumentation Demand
+
Oil & Gas
36.9%
+
Electronics
18.1%
+
Semiconductor R&D
16.7%
+
Pharma / Healthcare
~13%
+
Aerospace & Mfg
~8%
+
Other
~7%
+
Source: Future Market Insights synchrotron instrumentation report, 2025. Pharma/aerospace estimated from combined sources.
+
+
+
Strategic Observations
+
+
Large untapped industrial market
Only ~5% of ESRF users come from industry despite clear demand. Most companies never reach beamtime due to access friction, not lack of need.
+
Pharma is the anchor vertical
AstraZeneca alone generates ~800 unique protein-ligand structures per year. Drug discovery is the most mature and high-volume industrial use case.
+
9.2% CAGR through 2034
The market is nearly doubling in under 10 years. Battery technology, advanced alloys, and semiconductor scaling are driving new industrial demand.
+
Pricing benchmark: $790/hr
NSLS-II full cost-recovery proprietary rate. Scatterin positions as comparable to lab-scale cost at synchrotron quality, which is our same opportunity.
+
+
+
+
+ + +
+
+
+
Target Industry Verticals
+ +
+
Who buys beamtime and why, with confirmed industrial users at DESY
+ +
+
+
+
Pharmaceutical & Biotech
+
+
Highest volume user
Structural biology for drug discovery. AstraZeneca: ~800 protein-ligand structures/year. ESRF MXpress was built specifically for pharma mail-in service.
+
DESY confirmed clients
BioNTech (Ugur Sahin personally published SAXS work at PETRA III) and Captor Therapeutics are named DESY users.
+
+
Best-fit pitch: fastest path to structural data, no queue.
+
+
+
Aerospace & Advanced Manufacturing
+
+
Materials under stress
Fatigue analysis, weld integrity, composite microstructure. Beamtime reveals what CT and lab X-ray cannot at component scale.
+
Confirmed users
GKN Aerospace and OHB at DESY. Rolls-Royce and Airbus at Diamond and ESRF. TRUMPF using DESY for e-car copper welding.
+
+
Best-fit pitch: time-resolved in-situ measurements during mechanical loading.
+
+
+
Energy, Batteries & Semiconductors
+
+
Fastest growing segment
Li-ion battery development, hydrogen fuel cells, and catalyst research. Operando XRD during charge/discharge is growing demand. Johnson Matthey invested in Diamond specifically for fuel cells.
+
Semiconductors: real named users
STMicroelectronics has 4+ named researchers actively publishing ESRF beamtime work on phase-change memory and 3D IC characterisation.
+
+
Best-fit pitch: in-situ experiments under real operating conditions.
+
+
+
+
Confirmed Industrial Users at DESY PETRA III
+
+
BioNTech SE
Pharma / mRNA therapeutics
SAXS at PETRA III P12 — Ugur Sahin co-authored
+
Captor Therapeutics
Drug discovery
Macromolecular crystallography at PETRA III
+
GKN Aerospace
Aerospace components
Industrial measurements at PETRA III
+
OHB System AG
Space / satellite manufacturing
Industrial measurements at PETRA III
+
Hilti AG
Power tools / fastening systems
Materials characterisation at PETRA III
+
TRUMPF
Laser manufacturing / automotive
In situ X-ray imaging of EV copper welding at P07
+
Beiersdorf AG
Consumer / cosmetics
XRF nano-imaging at P06
+
Haldor Topsoe
Chemicals / catalysts
XAS/XRD catalyst characterisation
+
SKF
Bearings / industrial
Bearing materials research
+
+
+
+ + +
+
Customer Pain Points
Why industrial companies do not access beamtime directly — documented barriers from NSLS-II industry workshop and UKRI/ESRF impact reports
+
+
+
+
Unfamiliarity with synchrotron techniques
Most industrial R&D teams have never run a synchrotron experiment. They do not know what is measurable, what beamline to choose, or how to prepare samples.
+
No in-house expertise
Industrial teams lack the specialist knowledge to write competitive proposals, design experiments, or process the data post-collection.
+
Long lead times
Open-access beamtime is allocated competitively by review panels meeting 2-3 times per year. Industrial product cycles cannot wait 6-12 months for a slot.
+
High cost and payment terms
NSLS-II charges $790/hr with a 2-hour minimum and requires 100% advance payment. Without pre-existing relationships, the financial commitment is hard to justify.
+
Legal concerns with user agreements
Facility user agreements contain IP clauses that industrial legal teams find unfamiliar. Proprietary access routes require separate negotiations companies rarely know how to navigate.
+
No alternative instrument elsewhere
~70% of ESRF users said they could not pursue the same research without synchrotron access. There is no lab-scale substitute for many experiments.
+
+
+
+
Our Value Proposition
+
+
We close the expertise gap
We bring the synchrotron knowledge the client lacks. They describe their material problem; we design the experiment.
+
We eliminate queue time
Pre-booked beamtime and Wavegate technology cut experiment time and bypass competitive allocation queues. Results in weeks, not months.
+
We handle legal and admin
We hold the facility agreements. The client signs one contract with us, not a 30-page facility user agreement.
+
We prove the value first
The strongest sales motion is a pilot result. Show the client something they could not see before. The data sells the next project.
+
LinkedIn post angle
The time-resolution post targets engineers and R&D leads who have a materials problem but have never considered synchrotron. The post is the top of funnel. The pain points above are what the sales conversation closes on.
+
+
+
+
+ + +
+
Competitive Landscape
Known providers offering commercial synchrotron or beamtime-as-a-service
+
Scatterin AB is the most direct known competitor to our model. Others are sector-specific CROs. Facility-run programmes represent the status quo we are replacing.
+
+
+
Scatterin AB
Stockholm, Sweden — KTH spinoff • CEO: Ahmet Bahadir Yildiz
+
Pre-booked commercial access to European synchrotron and neutron facilities. End-to-end Measurement-as-a-Service: planning, sample prep, beamtime, and SaaS-delivered analysis. 1-2 week turnaround. Claims cost parity with lab-scale solutions. Confirmed clients: Hilti, Volvo Cars, Sandvik.
+
Closest match to usEuropean focus2-10 employees
+
+ scatterin.com + +
+
+
+
+
Company
+
Founded28 July 2021. KTH Royal Institute of Technology spinoff via KTH Innovation + KTH Ventures.
+
CEOAhmet Bahadir Yildiz — PhD Materials Science KTH / RWTH Aachen
+
CSOProf. Peter Hedstrom — KTH Professor, Director of CeXS and NEXT competence centre
+
Team size~7 people; Hamburg-based synchrotron expert (ex-DESY P21.2 beamline scientist 2020-2024)
+
FundingKTH Ventures (equity, Aug 2023); Vinnova grants SEK 2.55M confirmed; Ready2Scale EUR 60k (EU Horizon). Pre-seed, no VC round identified.
+
Tagline"Deeper insight. Faster loops. Better materials."
+
PricingNo public pricing. Claims "similar cost as lab-scale solutions" — unverified. All quotes bespoke.
+
+
+
Confirmed Facilities
+
DESY PETRA III (Hamburg) — P07 (online analysis 2 patterns/sec, Jul 2024) + P21.2 Swedish Materials Science beamline
+
MAX IV (Lund, Sweden) — live diffraction SaaS tested Jan 2026
+
ISIS (Didcot, UK) — neutron diffraction; Sandvik project Feb 2025
+
ESS (Lund) — listed as MAXESS industry partner; no public ESS case study yet
+
ESRF, Diamond, ILL: not publicly confirmed
+
+
+
+
+
Techniques
+
Synchrotron XRD (residual stress, strain gradients)
+
SAXS (minority phases, precipitates below 1 vol%)
+
XANES / EXAFS
+
Imaging, radiography, tomography (sub-micron)
+
Neutron diffraction (3D stress mapping, cm-depth in steel)
+
SANS
+
In-situ / operando (sub-second time resolution)
+
Bundled: SEM, TEM, EBSD (not confirmed in-house)
+
+
+
Target Verticals
+
Automotive (Volvo Cars — HPDC megacasting residual stress)
+
Tooling / advanced alloys (Sandvik, Hilti)
+
Aerospace
+
Energy systems (Hitachi Energy — NEXT Consortium)
+
Additive manufacturing, bearing steel
+
Pharma, battery, semiconductors: NOT marketed
+
+
+
+
Service Model
+
+
+
1. Plan
Define objectives, technique + facility selection +
+
→
+
+
2. Prepare
Sample prep, custom environments, safety compliance +
+
→
+
+
3. Measure
Pre-booked beamtime at European facilities +
+
→
+
+
4. Deliver
SaaS platform analysis, results in 1-2 weeks +
+
+
+
+
+
Their Differentiators (claimed)
+
Proprietary "Scatterin Platform" SaaS — live analysis at 2 patterns/sec during beamtime
+
Both synchrotron and neutron access from one provider
+
Pre-booked slots — no proposal writing, no queue
+
100% data confidentiality; client owns all results
+
+
+
Weaknesses vs Us
+
No Wavegate equivalent — no proprietary experiment time compression
+
Very small team (2-10) — capacity constraints at scale
+
No pharma, battery, or semiconductor vertical — large market gap
+
No confirmed ESRF or Diamond access — limited southern/UK coverage
+
Pricing opaque — "lab-scale cost" claim unverified
+
+
+
+
Recent Activity (2024-2026)
+
Feb 2026 — Volvo Cars HPDC megacast residual stress case study; FEM prediction validation
+
Jan 2026 — Live diffraction SaaS tested at MAX IV (fiber orientation analysis)
+
Jul 2025 — Hilti AG drill bit case study; Chief Scientist Steven Moseley quoted publicly
+
Feb 2025 — Sandvik cutting tool neutron diffraction at ISIS (Cr-doped hard metals)
+
Nov 2024 — Vinnova SEK 2M grant for product-market fit acceleration (runs to Mar 2026)
+
Nov 2023-2024 — ESAB partnership; in-situ XRD of high-strength steel welds at DESY PETRA III
+
Jul 2024 — DESY P07 SaaS pipeline: 2 diffraction patterns/sec live analysis confirmed
+
2023 — Brogren Industries + RISE aerospace engine components at PETRA III (Vinnova aviation grant)
+
Additional named clients: Ovako AB (bearing steel at PETRA III); Hitachi Energy (NEXT Consortium)
+
+
+
+ +
+
Momentum Transfer
Hamburg, Germany — DESY / BASF spinout
+
Commercial X-ray scattering data services, co-founded by DESY and BASF veterans. The BASF-to-Momentum-Transfer move by CSO Hinrichsen is the strongest public signal that industrial demand for this service is real.
+
Emerging competitorBASF / DESY pedigree
+
+ momentum-transfer.com + +
+
+
+
+
Company
+
Founded2023, Hamburg. Registered: District Court of Hamburg HRB 193795. Incubated via Chemovator (BASF's venture studio).
+
CEODr. Sebastian Winkler — synchrotron veteran
+
CSODr. Bernd Hinrichsen — 13 yrs BASF (Research Manager, XRD/SEM/TEM/NMR labs), ex-Bruker AXS, PhD MPI Stuttgart (Dinnebier lab)
+
COODr. Maxwell Terban — PDF specialist; ex-MPI Stuttgart (Dinnebier lab); PhD Columbia/BNL; h-index 30; 4,053 citations
+
Sci. AdvisoryProf. Simon Billinge (Columbia/BNL) and Prof. Robert Dinnebier (MPI Stuttgart) — direct PhD mentors of co-founders
+
FundingIFB (Investitionsbank Hamburg) grant, September 2025. Prior incubation via Chemovator (BASF venture studio).
+
+
+
Techniques and Facility
+
Beamline P25, DESY PETRA III (Hamburg) — confirmed operational base
+
Synchrotron powder X-ray diffraction (PXRD) — high-throughput
+
Total scattering and PDF (pair distribution function) — Terban's world-class specialism
+
Battery materials characterisation — the origin use case from BASF R&D
+
Catalysts, polymers, coatings, pigments, amorphous/nanostructured materials
+
+
+
+
+
Target Verticals
+
Battery / energy materials (born from BASF's battery crystal structure needs)
+
Chemicals and catalysis (Hinrichsen's BASF base; ESRF STREAMLINE co-design)
+
Advanced materials: polymers, coatings, nanostructured systems
+
Pharmaceuticals — Terban published on drug structure; likely a vertical
+
+
+
Weaknesses vs Us
+
One confirmed facility (DESY P25) — geographically concentrated in Hamburg
+
Technique narrow: PXRD / total scattering / PDF — no imaging, no MX, no neutrons (inferred)
+
No Wavegate equivalent — no proprietary experiment compression
+
Founded 2023 — very limited public case study track record
+
Website sparse; no published pricing or turnaround times
+
+
+
+
Strategic Signal
+
Hinrichsen spent 13 years at BASF managing central characterisation labs before leaving to co-found this. BASF co-designed ESRF's STREAMLINE powder diffraction service — he knows exactly what industrial demand looks like from the inside. That he saw the opportunity as large enough to leave one of the world's largest chemical companies is the single strongest independent validation of our market. Their BASF proximity also creates an acquisition angle: if Momentum Transfer grows, BASF or a similar industrial conglomerate is the obvious buyer.
+
+
+
+ + +
+
SARomics Biostructures AB
Lund, Sweden — Pharma structural biology CRO
+
Fragment screening and protein-ligand structure determination services for pharma drug discovery. Uses MAX IV and ESRF. CEO Bjorn Walse; CSO Derek Logan sits on the European Synchrotron and FEL User Organisation board.
+
Pharma vertical onlyPotential partner
+
+ saromics.com + +
+
+
+
+
Company
+
Founded2006 by 5 Lund University scientists. Based at Medicon Village since 2012, Lund (org. nr 556688-4150)
+
FoundersBjorn Walse, Derek Logan, Mikael Akke, Salam Al-Karadaghi, Bo Svensson
+
CEOBjorn Walse — co-founder, structural biologist
+
CSODerek Logan — co-founder, Associate Professor Lund University, ESUO board member
+
Size27 employees (Swedish registry); 21 visible on LinkedIn
+
Funding6 rounds, 8 investors (last round Sep 2017). Investors: Innovationsbron, LU Innovation System, Almi Invest, SmiLe, Sparbanken Skåne, LU Holding, European Investment Fund. No recent VC round identified.
+
RecentApr 2026: commercial partnership with Accelero Biostructures (San Francisco) — no equity change
+
PricingNo public pricing. Project-based quotes for pharma clients.
+
+
+
Facilities
+
MAX IV (Lund) — primary; started at predecessor MAX II; on-site proximity advantage
+
ESRF (Grenoble) — MX beamlines for structure determination
+
Diamond (Harwell, UK) — likely used (unconfirmed)
+
+
+
+
+
Services and Techniques
+
Macromolecular X-ray crystallography (MX)
+
Fragment-based drug discovery (FBDD) screening
+
Protein-ligand structure determination
+
SAXS for protein characterisation
+
Crystal optimisation and compound soaking
+
+
+
Target Verticals
+
Pharma drug discovery (Top 20 Big Pharma + biotech)
+
Fragment-to-lead programmes
+
Academic / non-profit research collaborations
+
No industrial/materials/energy vertical
+
+
+
+
+
Their Differentiators
+
20 years of operation — established pharma track record
+
MAX IV founding-era proximity — started at MAX II, co-evolved with the facility
+
CSO Derek Logan on ESUO board — direct facility governance relationships
+
Accelero Biostructures (SF) partnership — US pharma market reach (Apr 2026)
+
+
+
Weaknesses vs Us / Partnership Angle
+
Pharma only — zero presence in materials, energy, aerospace, automotive
+
No Wavegate equivalent — no time compression technology
+
Funding stalled since 2017 — limited growth capital for expansion
+
Partnership angle: SARomics handles pharma MX, we handle all other verticals and techniques — clean referral boundary
+
+
+
+
Recent Activity (2024-2026)
+
Apr 2026 — Commercial partnership with Accelero Biostructures (San Francisco) — US pharma market entry signal
+
Sep 2025 — FBLD 2025 (Cambridge): poster "A Platform for Efficient X-Ray Crystallography-Based Fragment Screening and Hit Evolution of Kinase Targets" — 15 SARomics authors + MAX IV collaboration
+
Apr 2024 — Drug Discovery Chemistry (San Diego): CEO Bjorn Walse oral presentation + poster on WAC fragment screening of IL-23
+
Nov 2023 — Multiple posters at PEGS Europe (Lisbon); Festival of Biologics (Basel)
+
+
+
+ + +
+
Proteros Biostructures GmbH
Munich, Germany — Large-scale structural biology CRO
+
Commercial X-ray crystallography and cryo-EM serving most Top 20 Big Pharma. Spun out of Max Planck Institute of Biochemistry. CEO Dr. Torsten Neuefeind. Largest and most established pharma structural CRO in Europe.
+
Pharma vertical onlyPotential partner
+
+ proteros.com + +
+
+
+
+
Company
+
Founded1999/2001, spinout from Max Planck Institute of Biochemistry (Nobel laureate Prof. Robert Huber lab), Martinsried
+
OwnershipAcquired by Inflexion Private Equity — growth/exit orientation
+
CEODr. Torsten Neuefeind — founder; PhD TU Munich (Huber lab); ex-McKinsey, Bayer
+
CBORyan Brady — 20+ yrs biopharma BD; ex-Evotec
+
CSODr. Horst Hemmerle — ex-Novartis, Eli Lilly, Aventis
+
Clients18 of the 20 largest global pharma companies; 250+ biotech partners across US, Europe, Japan
+
Scale700+ structures/year; 7,000+ total solved; 25+ structural biologists; 200+ Gallery Structures
+
+
+
Services and Techniques
+
Protein X-ray crystallography (MX) — core service; proprietary Free Mounting System (FMS)
+
Cryo-electron microscopy (cryo-EM)
+
Fragment-based drug discovery (FBDD); proprietary Picodropper soaking technology
+
Protein production, crystallisation, biochemical / biophysical assays
+
iLead integrated medicinal chemistry programme
+
Gallery Structures: 200+ pre-established targets for fast client access
+
+
+
+
+
Their Differentiators
+
Nobel Prize scientific heritage (Robert Huber, MPI) — strongest trust signal in the market
+
90%+ project success rate claimed; 700+ structures/year at scale
+
Proprietary FMS + Picodropper — hardware IP differentiates from all competitors
+
Full pipeline CRO: protein to structure to chemistry under one roof
+
No royalties; full IP transfer to client
+
AstraZeneca oncology collaboration announced 2022
+
+
+
Weaknesses vs Us / Partnership Angle
+
Pharma only — zero presence in materials, energy, automotive, aerospace
+
No Wavegate equivalent — no time compression technology
+
PE-owned: pricing pressure and potential staff churn concerns some pharma buyers
+
Single Martinsried site — geographic concentration risk
+
No public pricing or turnaround benchmarks — high-friction sales entry
+
Partnership angle: overflow/specialist referral for pharma MX we cannot serve at their volume
+
+
+
+
+ + +
+
Finden Ltd
Harwell, UK — XRD-CT industrial spinout
+
Specialists in XRD computed tomography for industrial materials. Antony Vamvakeros (Royal Society Industry Fellow) uses DESY PETRA III P07 and Diamond. 2023 RSC Analytical Science Horizon Prize. Direct overlap with our DESY access.
+
DESY P07 overlapPotential partner
+
+ finden.co.uk + +
+
+
Profile based on publicly known information — fresh web research pending (rate limit resets 12:40pm Berlin). Verify before using externally.
+
+
+
Company
+
LocationHarwell Science and Innovation Campus, UK
+
R&D LeadAntony Vamvakeros — Royal Society Industry Fellow, Imperial College London (confirmed LinkedIn)
+
Award2023 RSC Analytical Science Horizon Prize for XRD-CT work
+
AffiliationClose ties to Diamond Light Source (Harwell campus) and DESY Hamburg
+
PricingNo public pricing found
+
+
+
Facilities
+
DESY PETRA III P07 (Hamburg) — confirmed for industrial XRD-CT
+
Diamond Light Source (Harwell, UK) — on-site proximity; I12 JEEP likely
+
ESRF (Grenoble) — used in published research
+
+
+
+
+
Services and Techniques
+
XRD-CT (X-ray diffraction computed tomography) — core specialism
+
SAXS-CT and fluorescence-CT
+
nDTomo software (open-source data processing for XRD-CT)
+
In-situ / operando tomography under reaction conditions
+
Catalyst characterisation, battery materials, industrial process monitoring
+
+
+
Target Verticals
+
Catalysis / chemicals (core published work)
+
Energy / batteries
+
Industrial process monitoring
+
Aerospace materials (likely, given DESY P07 access)
+
+
+
+
+
Their Differentiators
+
World-leading XRD-CT expertise — Vamvakeros pioneered the technique industrially
+
Open-source nDTomo software builds scientific credibility
+
RSC Prize and Royal Society Fellowship — high academic legitimacy
+
Diamond proximity — fastest UK access route
+
+
+
Weaknesses vs Us / Partnership Angle
+
XRD-CT only — very narrow technique portfolio
+
No Wavegate equivalent
+
UK-centric — limited continental European client base (inferred)
+
Strong partnership angle: they handle XRD-CT; we refer clients needing broader technique range
+
+
+
+
+ + +
+
ESRF MXpress / NSLS-II Proprietary
Facility-run programmes — the status quo we replace
+
ESRF's mail-in MX service (running since 2002) and NSLS-II's proprietary industrial access at $790/hr. These are the programmes clients use before they find us. We offer the same data faster, with more expertise, under one contract.
+
Facility-runStatus quo to displace
+
+ esrf.fr/Industry + bnl.gov/nsls2/industry + +
+
+
+
+
ESRF MXpress
+
Running since2002 — the original industrial mail-in synchrotron service
+
TechniqueMacromolecular X-ray crystallography (MX) only
+
ProcessClient ships crystals by post; ESRF collects data remotely on ID23 / ID30 beamlines; data returned electronically
+
TurnaroundWeeks to months depending on queue and programme slot availability
+
PricingProprietary access pricing not publicly disclosed; academic MX access is free via proposal; industrial access is priced separately
+
Key contactAthanasios Papazoglou (Business Developer, ESRF) — see Contacts tab
+
+
+
NSLS-II Industrial / Proprietary Access
+
LocationBrookhaven National Lab, Upton, New York, USA
+
Pricing~$790/hr with 2-hour minimum; 100% advance payment required
+
TechniquesWide range across 28 beamlines: XRD, SAXS, imaging, spectroscopy, MX
+
ProcessDirect booking via proprietary access route; no competitive proposal required but full user safety training needed
+
Key contactJun Wang, Physicist Industrial Program Officer — junwang@bnl.gov / +1 (631) 344-2661
+
+
+
+
Why Clients Leave Facility Programmes and Come to Us
+
No experiment expertise included — client must know what they want and how to interpret results
+
Long lead times even on proprietary routes — scheduling around academic beam use
+
Complex legal agreements — facility user contracts with IP clauses require legal review
+
NSLS-II requires 100% advance payment and mandatory safety training — high friction for first-timers
+
Geography: NSLS-II is US-only; ESRF MXpress is pharma-only (MX technique)
+
Our advantage: one contract, full expertise, Wavegate speed, broader technique access across multiple European facilities
+
+
+
+
+
+ + +
+
Key Contacts
Organized by category: facility liaisons, competitors, and prospects
+
LinkedIn URLs not directly confirmed unless stated. Names, titles, and emails sourced from official facility and company websites. Search LinkedIn by name + company for direct profile links.
+ +
+ +
+
+ + + + + + + + + + +
NameTitleFacilityContactNotes
Dr. Sabine BrockDeputy CTO, Head of Industry RelationsDESY Innovation & Technology TransferSearch LinkedInSenior strategic contact. Presents DESY at trade fairs and builds industrial partnerships. Priority relationship.
Dr. Saiva HuckIndustry Cooperation, Photon ScienceDESYSearch LinkedInDirect gatekeeper for PETRA III and PETRA IV industrial access.
Oliver WendtManager Innovation Services, Business DevelopmentDESYSearch LinkedInMost accessible entry point at DESY. Named contact for industrial case studies.
Dr. Dirk KlugmannManager Innovation Services PETRA IVDESYSearch LinkedInDeveloping PETRA IV industrial business cases. Forward-looking contact.
Dr. Nadja KolpinPlatform Management Hi-ActsDESYSearch LinkedInCentral contact for Hi-Acts industry network at DESY.
Jun WangPhysicist, Industrial Program OfficerNSLS-II, Brookhaven National Lab+1 (631) 344-2661Named industrial liaison for all NSLS-II commercial access. Verified source.
Athanasios PapazoglouBusiness DeveloperESRF, GrenobleSearch LinkedInWorks directly with industrial clients at ESRF. Managed BASF STREAMLINE project.
+
+
+ +
+ +
+
+ + + + + + + + + + +
CompanyNameTitleContactNotes
Scatterin ABAhmet Bahadir YildizCEO & Co-founderLinkedIn (confirmed)KTH spinoff. Closest direct competitor to our model. Pre-booked beamtime + end-to-end service at DESY P07/P21.2, MAX IV, ISIS, ESS.
Scatterin ABProf. Peter HedstromCSO & Co-founderLinkedIn (confirmed)KTH Professor; Director of CeXS and NEXT competence centre. Scientific credibility anchor for Scatterin. Strong facility relationships at DESY and MAX IV.
Momentum TransferDr. Sebastian WinklerCEO & Co-founderSearch LinkedInSynchrotron veteran. Emerging direct competitor at DESY P25. Watch closely.
Momentum TransferDr. Bernd HinrichsenCSO & Co-founderLinkedIn (confirmed)13 yrs at BASF (XRD/SEM/TEM/NMR labs). Left to co-found Momentum Transfer. Strongest public signal of industrial demand for our market.
Finden LtdAntony VamvakerosR&D Lead Scientist; Royal Society Industry FellowLinkedIn (confirmed)XRD-CT pioneer, 2023 RSC Horizon Prize. Uses DESY PETRA III P07. Potential partner for XRD-CT referrals.
SARomics Biostructures ABBjorn WalseCEO & Co-founderSearch LinkedInPharma-only structural CRO. Founded 2006 at MAX II. US expansion via Accelero Biostructures (Apr 2026). Partnership angle: they do pharma MX, we do everything else.
Proteros Biostructures GmbHDr. Torsten NeuefeindCEO & FounderLinkedIn (confirmed)Largest pharma structural CRO in Europe. 18/20 Big Pharma clients. PE-owned (Inflexion). Potential overflow/white-label partner for pharma MX.
+
+
+ +
+ +
+
Budget Holder = signs off on spend.   Champion = uses the data, can build internal case.   Technical = end user, not a buyer.   Find Contact = no named person yet, LinkedIn search ready.
+
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
CompanyNamed Contact + TitleRoleVerticalStatusWebsiteLinkedInPitch AngleWho to Contact
Pharma & Life Sciences
BioNTech SEHeinrich Haas
Senior Scientist / R&D		ChampionPharma / mRNAWarmbiontech.comH. HaasUgur Sahin personally co-authored SAXS study at PETRA III P12. Beamtime is embedded in their R&D pipeline.Contact Haas as technical champion. Budget holder: Head of Structural Biology / VP R&D.
Idorsia PharmaceuticalsDaniel Ritz
Senior Director of Biology		Budget HolderPharma / Drug DiscoveryWarmidorsia.comSearch LinkedInUsed ESRF ID23-1 for COVID drug discovery. Publicly quoted — high-quality named outreach target.Direct outreach to Ritz. Senior Director = budget authority. Use the ESRF ID23-1 work as the opener.
leadXpro AGRobert Kin Yip Cheng
Head of Biochemistry		ChampionPharma / Membrane ProteinsWarmleadxpro.comSearch LinkedInPSI spin-out. Ran the first-ever industrial serial crystallography on ESRF ID29 (Feb 2026).Cheng is the right technical entry. Small company — CEO approves budget. Build the case through Cheng first.
AstraZenecaHelena Kack, Tove Sjogren
Scientists, Structural Biology (Gothenburg)		TechnicalPharma / Drug DiscoveryPipelineastrazeneca.comH. Kack T. Sjogren~800 structures/year. May outsource overflow or specialist runs.Kack and Sjogren are technical users, not buyers. Budget held by Head of Structural Biology or VP Drug Discovery, Gothenburg. Use them as champions.
CrystalsFirstSerghei Glinca
Founder and CEO		Budget HolderPharma / Drug DiscoveryWarmcrystalsfirst.comSearch LinkedInActive DESY P11 partnership for fragment-based drug discovery. Potential partner or client.Founder/CEO = budget holder and decision maker in one. Accessible startup contact. Direct outreach.
GSKNo named contact yet
Find: Head of Structural Biology		Find ContactPharmaPipelinegsk.comSearch LinkedInConfirmed Diamond Light Source industrial user.Find Head of Structural Biology or Protein Sciences — that person manages the synchrotron relationship. Budget held by VP Drug Discovery.
Aerospace & Defence
Rolls-RoyceDavid Rugg
Senior Fellow, Materials		ChampionAerospace / TurbinesWarmrolls-royce.comSearch LinkedInUsed Diamond I12 for Trent 1000 turbofan blade XRD. First industrial user of the JEEP beamline.Rugg is the champion but not the buyer. Budget held by VP Materials / Director of Advanced Technology. Use Rugg to escalate.
GKN AerospaceNo named contact yet
Find: Head of Materials Characterisation		Find ContactAerospace / CompositesWarmgknaerospace.comSearch LinkedInConfirmed DESY PETRA III user. Same data, less friction, faster turnaround.No named contact yet. Search LinkedIn for Head of Materials Science or Advanced Characterisation. Budget holder: VP Engineering / Director of Materials Technology.
AirbusCecile Weulersse
Radiation/SEE Test Engineer, 20+ yrs		TechnicalAerospace / Space SystemsPipelineairbus.comSearch LinkedInUsed ESRF ID09 for satellite chip radiation/SEE testing.Weulersse is the technical user, not the buyer. Budget held by Radiation Test Programme Manager or VP Space Systems. Use her as a reference entry point.
Energy & Chemicals
Johnson MattheyDr Elizabeth Rowsell OBE
CTO		Budget HolderEnergy / Fuel CellsWarmmatthey.comSearch LinkedInDrove JM's Diamond I14 investment for platinum group metals and hydrogen fuel cells.CTO = budget holder. Highest-level warm entry in the dataset. Direct outreach appropriate.
BASF SENo named contact yet
Find: Head of XRD / Advanced Characterisation, Ludwigshafen		Find ContactChemicals / CatalysisPipelinebasf.comSearch LinkedInCo-designed ESRF STREAMLINE powder diffraction service. Hinrichsen left to found Momentum Transfer — his replacement holds the relationship.Find new Head of Advanced Characterisation in Ludwigshafen. Budget held by VP Corporate Research.
Siemens EnergyNo named contact yet
Find: Head of Materials R&D or Advanced Manufacturing		Find ContactEnergy / TurbinesPipelinesiemens-energy.comSearch LinkedInTurbine blade and high-temperature alloy characterisation. In-situ strain measurement under service conditions is the key use case.Find Head of Advanced Materials or VP R&D Turbines. Budget held at VP level.
TopsoeNo named contact yet
Find: Head of Catalysis Characterisation		Find ContactChemicals / CatalystsPipelinetopsoe.comSearch LinkedInConfirmed DESY PETRA III user for XAS/XRD catalyst characterisation.Find the person managing external characterisation experiments. Budget held by VP R&D / Head of Catalysis.
Automotive & Advanced Manufacturing
TRUMPFDr. Mauritz Moller
Automotive Industry Manager		ChampionAutomotive / Laser MfgWarmtrumpf.comSearch LinkedInUsed DESY P07 for in situ X-ray of EV copper welding. Publicly quoted.Moller is the right first contact. Budget held by VP Advanced Manufacturing R&D. Use Moller to reach the buyer.
BMW GroupNo named contact yet
Find: Head of Battery Cell Characterisation or Materials R&D		Find ContactAutomotive / BatteryPipelinebmwgroup.comSearch LinkedInKnown synchrotron user for battery cell and lightweight materials research.Find Head of Battery Cell Characterisation or Materials R&D. Budget held by VP Battery Technology.
VerkorBenoît Lemaignan
CEO & Co-founder		Budget HolderAutomotive / EV BatteryPipelineverkor.comB. LemaignanFrench EV battery startup building a 16 GWh gigafactory in Dunkirk. €2B+ funded. R&D centre near Grenoble — ESRF is on the doorstep. Operando XRD/XAS essential for NMC cathode and solid-state electrolyte development.Lemaignan is CEO but find CTO or Head of Cell R&D for technical entry. ESRF proximity makes the pitch immediate — no long travel or logistics friction.
Volkswagen PowerCoNo named contact yet
Find: Head of Cell Chemistry or Materials Characterisation		Find ContactAutomotive / EV BatteryPipelinevolkswagen-powerco.comSearch LinkedInVW's dedicated battery subsidiary building 6 gigafactories across Europe. Operando synchrotron XRD/XAS is essential for cell chemistry R&D and process qualification at scale.Find Head of Cell Chemistry or Advanced Characterisation. Budget held by CTO PowerCo. Large org — technical champion entry first, then escalate.
Semiconductors & Electronics
STMicroelectronicsPhilipp Hans
Researcher, Materials Physics		TechnicalSemiconductorsPipelinest.comSearch LinkedIn3 published ESRF ID01 studies (2022–2025) on phase-change memory. Active and recurring beamtime user.Hans is the user, not the buyer. Budget held by Director of Advanced Characterisation or VP R&D. Reach Hans first, then escalate to his department head.
TSMC DresdenNo named contact yet
Find: Head of Process R&D or Materials Engineering, Dresden		Find ContactSemiconductors / Advanced NodesPipelinetsmc.comSearch LinkedInFirst TSMC fab in Europe, opening ~2027. €10B investment. Unlike Taiwan, no NSRRC equivalent nearby. Process qualification at advanced nodes requires XRD, XRR, SAXS. DESY Hamburg is ~600km away.Fab is in qualification phase 2025-2027 — highest characterisation need is now. Find Head of Process Integration or Materials Engineering in Dresden. Budget held by VP Technology Europe.
Infineon TechnologiesNo named contact yet
Find: Head of Advanced Process R&D, Dresden		Find ContactSemiconductors / Automotive ChipsPipelineinfineon.comSearch LinkedInExpanding Smart Power Fab in Dresden for automotive power electronics. EV drivetrain and SiC chip demand driving scale-up. Thin film XRD and XRR essential for power device process control.Find Head of Materials Characterisation or Process R&D at Dresden fab. Budget held by VP R&D / Head of Frontend Manufacturing.
BoschNo named contact yet
Find: Head of Materials R&D, Semiconductor Division or Hydrogen R&D		Find ContactSemiconductors + Energy / HydrogenPipelinebosch.comSearch LinkedInOperating automotive chip fab in Dresden (opened 2021). Also developing hydrogen electrolysis technology. Dual characterisation need: semiconductor process control (XRD/XRR) + catalyst XAS for hydrogen R&D.Two separate entry points: semiconductor division (Dresden fab) and hydrogen/fuel cell R&D. Budget held at VP level in each division. Two-angle approach recommended.
Consumer
Beiersdorf AGThomas Blatt
Principal Scientist; DESY Foundation Council		ChampionConsumer / CosmeticsWarmbeiersdorf.comSearch LinkedInUsed PETRA III P06 XRF. On DESY Foundation Council — best-connected warm lead in Hamburg.Blatt can champion internally. Budget holder: VP R&D / Head of Advanced Analytics.
+
+
+
+ + +
+
Sources
All research sources organized by category. Data collected June 2026 via automated web research.
+ +
+
Market SizingReports used for global market value, CAGR, and vertical breakdown figures.
+
+ + + + + + + + + +
SourceKey Data PointLink
Data Horizzon ResearchGlobal synchrotron market $1.5B (2024) to $3.2B (2033), CAGR 9.2%View report
Verified Market ReportsCorroborating $1.5B (2025) to $3.2B (2034) figuresView report
Future Market InsightsInstrumentation $1.2B to $2.0B, CAGR 5.6%; Oil & Gas 36.9%, Electronics 18.1%, Semiconductors 16.7%View report
UKRI / ESRF Impact Evaluation (2023)~5% of ESRF users from industry (2011-2021); pain points documentedView PDF
NSLS-II Proprietary Research Policy$790/hr FY2026; 100% advance payment; 2-hour minimumView PDF
NSLS-II Industry Workshop Report (2020)Documented barriers: unfamiliarity, no expertise, long lead times, cost, legal concernsView PDF
+
+ +
+
Industrial Users — ESRFNamed individuals and case studies from ESRF facility publications.
+
+ + + + + + + + + +
SourceContacts / DataLink
ESRF: Idorsia drug discoveryDaniel Ritz and Julien Hazemann — SARS-CoV-2 Mpro inhibitor at ID23-1View article
ESRF: Airbus satellite chip testingCecile Weulersse — pulsed X-ray SEE testing of 3D stacked memory, ID09View article
ESRF: First industrial serial crystallography on ID29 (2026)Robert Kin Yip Cheng (leadXpro AG) — membrane protein drug discoveryView article
Wiley: In Situ XRD on GST (STMicro, 2022)Philipp Hans, Yannick Le-Friec, Roberto Simola — phase-change memory at ESRF ID01View paper
PMC: Macromolecular crystallography (AstraZeneca)Helena Kack and Tove Sjogren — ~800 protein-ligand structures/yearView paper
PMC: How ESRF helps industry (2013)Edward P. Mitchell (Business Development, ESRF)View paper
+
+ +
+
Industrial Users — DESY PETRA IIINamed individuals and case studies from DESY innovation pages and publications.
+
+ + + + + + + + + +
SourceContacts / DataLink
PMC: BioNTech mRNA nanoparticle SAXS studyUgur Sahin, Heinrich Haas, Sara Nogueira — SAXS at PETRA III P12View paper
DESY Innovation: Beiersdorf CoQ10 studyThomas Blatt (Principal Scientist + DESY Foundation Council) — XRF at P06View article
DESY Innovation: CrystalsFirst partnershipSerghei Glinca (CEO) — fragment-based drug discovery at P11View article
TRUMPF press release: e-car laser weldingDr. Mauritz Moller (Automotive Industry Manager) — in situ X-ray at P07View article
PETRA IV Campaign Start: BASFBernd Hinrichsen (Manager Research, BASF) — PETRA IV industrial panelView article
DESY Innovation: Industrial case studies indexGKN Aerospace, OHB, Hilti, BioNTech, Captor, Haldor Topsoe, SKF, Beiersdorf confirmedView index
+
+ +
+
Industrial Users — Diamond Light SourceNamed individuals from Diamond industrial case studies (Harwell, UK).
+
+ + + + + + +
SourceContacts / DataLink
Diamond: Rolls-Royce fan blade case studyDavid Rugg (Senior Fellow for Materials) — in situ XRD at I12View case study
Johnson Matthey / Diamond I14 investment (2023)Dr Elizabeth Rowsell OBE (CTO) — platinum group metals for hydrogen fuel cellsView article
Diamond: Engineering case studies indexRolls-Royce, GSK, Unilever mentioned as industrial usersView index
+
+ +
+
CompetitorsSources for commercial beamtime service providers.
+
+ + + + + + + +
SourceKey DataLink
Scatterin AB websitePre-booked beamtime, 1-2 week delivery, lab-comparable pricingView site
Momentum Transfer websiteCo-founders Winkler, Hinrichsen (ex-BASF), TerbanView team
Antony Vamvakeros LinkedIn (Finden Ltd)R&D Lead, XRD-CT at DESY P07; direct LinkedIn confirmedView profile
NSLS-II Industry pageJun Wang contact; access modes (general, proprietary, rapid)View page
+
+
+ +
+ + + + \ No newline at end of file